740 related articles for article (PubMed ID: 23816768)
41. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems.
Bhatia R; Murphy AB; Raper JL; Chamie G; Kitahata MM; Drozd DR; Mayer K; Napravnik S; Moore R; Achenbach C;
AIDS; 2015 Jan; 29(1):77-81. PubMed ID: 25387318
[TBL] [Abstract][Full Text] [Related]
42. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
[TBL] [Abstract][Full Text] [Related]
43. A small-scale clinical trial to determine the safety and efficacy of testosterone replacement therapy in hypogonadal men with spinal cord injury.
Bauman WA; Cirnigliaro CM; La Fountaine MF; Jensen AM; Wecht JM; Kirshblum SC; Spungen AM
Horm Metab Res; 2011 Jul; 43(8):574-9. PubMed ID: 21717386
[TBL] [Abstract][Full Text] [Related]
44. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).
Maggi M; Wu FC; Jones TH; Jackson G; Behre HM; Hackett G; Martin-Morales A; Balercia G; Dobs AS; Arver ST; Maggio M; Cunningham GR; Isidori AM; Quinton R; Wheaton OA; Siami FS; Rosen RC;
Int J Clin Pract; 2016 Oct; 70(10):843-852. PubMed ID: 27774779
[TBL] [Abstract][Full Text] [Related]
45. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
Hackett G; Cole N; Mulay A; Strange RC; Ramachandran S
BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
[TBL] [Abstract][Full Text] [Related]
46. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
[TBL] [Abstract][Full Text] [Related]
47. Long-term treatment patterns of testosterone replacement medications.
Donatucci C; Cui Z; Fang Y; Muram D
J Sex Med; 2014 Aug; 11(8):2092-9. PubMed ID: 24909541
[TBL] [Abstract][Full Text] [Related]
48. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
49. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
[TBL] [Abstract][Full Text] [Related]
50. Patients with testosterone deficit syndrome and depression.
Khera M
Arch Esp Urol; 2013 Sep; 66(7):729-36. PubMed ID: 24047633
[TBL] [Abstract][Full Text] [Related]
51. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial.
Glintborg D; Vaegter HB; Christensen LL; Bendix E; Graven-Nielsen T; Andersen PG; Andersen M
Eur J Endocrinol; 2020 Jun; 182(6):539-548. PubMed ID: 32213659
[TBL] [Abstract][Full Text] [Related]
52. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients.
Strollo F; Strollo G; Morè M; Magni P; Macchi C; Masini MA; Carucci I; Celotti F; Ruscica M; Gentile S
Aging Male; 2013 Jun; 16(2):33-7. PubMed ID: 23517433
[TBL] [Abstract][Full Text] [Related]
53. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
54. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
Behre HM; Heinemann L; Morales A; Pexman-Fieth C
Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
[TBL] [Abstract][Full Text] [Related]
55. Testosterone replacement therapy improves QTaVI in hypogonadal men with spinal cord injury.
La Fountaine MF; Wecht JM; Cirnigliaro CM; Kirshblum SC; Spungen AM; Bauman WA
Neuroendocrinology; 2013; 97(4):341-6. PubMed ID: 23343764
[TBL] [Abstract][Full Text] [Related]
56. Testosterone replacement in men.
Beg S; Al-Khoury L; Cunningham GR
Curr Opin Endocrinol Diabetes Obes; 2008 Aug; 15(4):364-70. PubMed ID: 18594278
[TBL] [Abstract][Full Text] [Related]
57. Absorption of testosterone gel 1% (Testim) from three different application sites.
Guay AT; Smith TM; Offutt LA
J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy.
Rietschel P; Corcoran C; Stanley T; Basgoz N; Klibanski A; Grinspoon S
Clin Infect Dis; 2000 Nov; 31(5):1240-4. PubMed ID: 11073758
[TBL] [Abstract][Full Text] [Related]
59. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
Saad F; Yassin A; Doros G; Haider A
Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
[TBL] [Abstract][Full Text] [Related]
60. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
